Share on StockTwits

Masimo Corp. (NASDAQ:MASI)‘s stock had its “neutral” rating reaffirmed by Zacks in a report released on Tuesday, reports. They currently have a $29.00 price objective on the stock. Zacks‘ target price indicates a potential upside of 4.39% from the company’s current price.

Zacks‘ analyst wrote, “Masimo Corporation saw a 19.2% rise in EPS that met the Zacks Consensus Estimate in the fourth quarter of 2013. However, revenues of $142.4 million missed the mark in the quarter. For 2014, MASI expects higher revenues of $578 to $598 million versus 2013. The company’s SET offering may help it become a dominant global player in the pulse oximetry market. Its SET offering shipments were flat in the fourth quarter. However, we note sluggish growth rates in the quarter. Further, soft economic recovery raises concern and strong competition is a headwind. We maintain our Neutral recommendation on Masimo and set a target price of $29.00.”

Masimo Corp. (NASDAQ:MASI) traded up 0.90% during mid-day trading on Tuesday, hitting $28.03. 618,954 shares of the company’s stock traded hands. Masimo Corp. has a 52-week low of $19.03 and a 52-week high of $32.20. The stock has a 50-day moving average of $29.75 and a 200-day moving average of $27.59. The company has a market cap of $1.586 billion and a price-to-earnings ratio of 27.24.

Masimo Corp. (NASDAQ:MASI) last released its earnings data on Thursday, February 13th. The company reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. The company had revenue of $134.70 million for the quarter, compared to the consensus estimate of $148.25 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. Analysts expect that Masimo Corp. will post $1.17 EPS for the current fiscal year.

Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.

To view Zacks’ full report, visit

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.